Raredr

Gastric Cancer Treatment Receives Orphan Drug Designation

RDR Staff
Published Online: Thursday, Feb 16, 2017
Zymeworks’ orphan drug ZW25 for the treatment of gastric cancer and cancer of the gastroesophageal junction (GEJ) has been granted Orphan Drug Designation by the FDA.
 
ZW25 is currently being evaluated in an adaptive Phase 1 clinical trial in patients with advanced HER2 expressing cancers.
 
ZW25 is a bispecific antibody that is designed to simultaneously bind two non-overlapping epitopes, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and enhanced effector function.
 
The drug was also granted Orphan Drug Designation intended for ovarian cancer last year. 

About gastric cancer

Gastric (stomach) cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. The stomach is in the upper abdomen and helps digest food.
 
Almost all gastric cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Other types of gastric cancer are gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, and lymphomas.
 
Gastric cancer is often diagnosed at an advanced stage because there are no early signs or symptoms.
 


Latest Articles
On July 25, the Judge will decide the fate of Charlie Gard. What he decides may lean towards the hippocratic oath: First, do no harm.
In a recent interview with Chelsea Handler on her Netflix talk show, Harry Styles confirmed an internet rumor that he has 4 nipples, or 2 supernumerary nipples.
News from NORD and its Member Organizations
As of 18 months after surgery, the child is now able to write, feed, and dress himself more independently and efficiently.
$vacMongoViewPlus$ $vAR$